Ads by Google
Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment of insomnia.
Results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP with 90Yttrium Ibritumomab Tiuxetan radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma are promising.
Pharmacyclics announced final data from a Phase 1/2 study showing a 46 percent complete response rate in patients with multiply recurrent non-Hodgkin's lymphoma (NHL).
Rigel reported an abstract providing preliminary results of a Phase 2 clinical trial of its oral Syk inhibitor, R788, in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas.
Amicus Therapeutics has initiated a Phase 2 clinical trial of AT2220, for the treatment of Pompe disease.
Wyeth Pharmaceuticals initiates INTORACT study, a worldwide randomized, open-label, phase 3b study comparing TORISEL plus Avastin versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma.
CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI).
Quest PharmaTech's 12-patient, Phase I clinical study entitled "ACP-SL017 Topical Gel: A Phase I Study for the Photodynamic Therapy of Actinic Keratosis" has met both its primary and exploratory objectives.
ViroPharma Incorporated completed enrollment in its pivotal Phase 3 study of maribavir in stem cell transplant patients. This international Phase 3 study is evaluating the efficacy, safety and tolerability of prophylactic use of maribavir administered orally for up to 12 weeks for the prevention of cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT). The study also will evaluate the pharmacokinetics of maribavir in this subject population. It is being conducted in 90 transplant centers in the U.S., Canada, and Europe.
Favrille announced results from Phase 3 registration trial of Specifid following Rituxan in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).
The 56 medical scientists that receive the $600 million funding for medical research will bring new and innovative ways of thinking about biology to the HHMI community.
Tioga Pharmaceuticals announced the results of a recent Phase 2b study of its oral kappa opioid receptor agonist, asimadoline, which demonstrated statistically significant results in the treatment of Irritable Bowel Syndrome.
Amikacin Inhale, currently being studied for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients, achieved over 1000 times greater lung exposure to the antibiotic amikacin as compared to intravenous route of administration.
The use of Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations as compared with salmeterol alone.
Patients with Lennox-Gastaut syndrome treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo.
Palatin Technologies has initiated dosing in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.
TAP Pharmaceutical Products reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor with an innovative dual delayed release technology, in healing patients with erosive esophagitis and in maintenance of healed EE.
Pharmasset has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys plus Copegus in both treatment-naive and treatment-experienced patients chronically-infected with hepatitis C virus genotypes 1, 2 and 3.
Oncolytics Biotech has received a letter of approval from MHRA for its CTA to begin a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
Medical research has made great progress in preventing, detecting and treating cancer over the past 25 years, but the benefits of that success do not extend to adolescents and young adults.
National Poll on Children's Health finds many parents willing to let children take part in medical research if risk of harm is minimal.
Velcura Therapeutics announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis and other bone diseases.
Roche's investigational therapy for chronic hepatitis C virus infection, R1626, has shown a significant end-of-treatment response rate when given in combination with PEGASYS and COPEGUS.
Study that was designed to evaluate the adjuvant use of Xibrom 0.09% in Lucentis treatment of choroidal neovascularization secondary to age-related macular degeneration showed promising results.
Developing blood substitude is a great medical advance, but a new study raises some serious concerns about the rush to bring these artificial blood substitutes to the market.
Roche's three studies indicate that chronic hepatitis C patients who received PEGASYS plus ribavirin had a greater chance of achieving a sustained virological response than patients on peginterferon alfa-2b.
Micromet starts phase 1 clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
PTC Therapeutics initiates an international pivotal trial of PTC124 in patients with Duchenne/Becker muscular dystrophy (DMD/BMD) due to a nonsense mutation. The primary objective of this registration-directed Phase 2b trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.
Sysmex America announced the successful completion of Mercy Medical Center's (Canton, OH) beta studies for its integrated hematology and A1C automation solution. This first-of-kind solution, which combines the Sysmex HST-N hematology automation platform and the Bio-Rad Laboratories, Inc. VARIANT II TURBO Link, enables on-demand, automated diabetes testing in a random access setting.
Elusys Therapeutics announced pivotal animal efficacy results of Anthim, a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.
